CN112367974A - 粘液穿透肽、递送媒介和治疗方法 - Google Patents

粘液穿透肽、递送媒介和治疗方法 Download PDF

Info

Publication number
CN112367974A
CN112367974A CN201980045452.2A CN201980045452A CN112367974A CN 112367974 A CN112367974 A CN 112367974A CN 201980045452 A CN201980045452 A CN 201980045452A CN 112367974 A CN112367974 A CN 112367974A
Authority
CN
China
Prior art keywords
peptide
composition
delivery vehicle
mucus
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980045452.2A
Other languages
English (en)
Chinese (zh)
Inventor
马布西吉·艾哈迈德
蒂莫西·保罗·戴
卡珊德拉·考曼
朱茜茜
伊斯梅尔·哈菲兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Particella Inc
Original Assignee
Dnalite Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnalite Therapeutics Inc filed Critical Dnalite Therapeutics Inc
Publication of CN112367974A publication Critical patent/CN112367974A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980045452.2A 2018-05-15 2019-05-15 粘液穿透肽、递送媒介和治疗方法 Pending CN112367974A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671709P 2018-05-15 2018-05-15
US62/671,709 2018-05-15
PCT/US2019/032484 WO2019222400A2 (en) 2018-05-15 2019-05-15 Mucus-penetrating peptides, delivery vehicles and methods of therapy

Publications (1)

Publication Number Publication Date
CN112367974A true CN112367974A (zh) 2021-02-12

Family

ID=68540758

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980045452.2A Pending CN112367974A (zh) 2018-05-15 2019-05-15 粘液穿透肽、递送媒介和治疗方法

Country Status (7)

Country Link
US (1) US20210177982A1 (https=)
EP (1) EP3796892A2 (https=)
JP (1) JP2021523912A (https=)
CN (1) CN112367974A (https=)
AU (1) AU2019269590A1 (https=)
CA (1) CA3100020A1 (https=)
WO (1) WO2019222400A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230023615A1 (en) * 2019-12-13 2023-01-26 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
US20230346700A1 (en) * 2020-02-19 2023-11-02 University Of Florida Research Foundation, Incorporated Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors
WO2022260678A1 (en) * 2021-06-11 2022-12-15 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
EP4259099A1 (en) 2020-12-14 2023-10-18 Particella, Inc. Biological delivery systems

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110020280A1 (en) * 2008-02-28 2011-01-27 Toray Industries, Inc. Pharmaceutical composition for transnasal administration
US20170246320A1 (en) * 2011-02-08 2017-08-31 The Johns Hopkins University Mucus penetrating gene carriers
WO2018013907A1 (en) * 2016-07-15 2018-01-18 Board Of Regents, The University Of Texas System Mucus-penetrating peptides and screening assay
WO2018053434A1 (en) * 2016-09-16 2018-03-22 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US176111A (en) 1876-04-11 Improvement in car-couplings
CA2863632C (en) * 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
AU2013256064B2 (en) * 2012-05-03 2018-01-04 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
KR101669203B1 (ko) * 2014-06-18 2016-10-25 한국과학기술연구원 신규 세포투과성 펩타이드 및 이의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110020280A1 (en) * 2008-02-28 2011-01-27 Toray Industries, Inc. Pharmaceutical composition for transnasal administration
US20170246320A1 (en) * 2011-02-08 2017-08-31 The Johns Hopkins University Mucus penetrating gene carriers
WO2018013907A1 (en) * 2016-07-15 2018-01-18 Board Of Regents, The University Of Texas System Mucus-penetrating peptides and screening assay
WO2018053434A1 (en) * 2016-09-16 2018-03-22 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery

Also Published As

Publication number Publication date
EP3796892A2 (en) 2021-03-31
JP2021523912A (ja) 2021-09-09
WO2019222400A3 (en) 2020-02-13
CA3100020A1 (en) 2019-11-21
WO2019222400A2 (en) 2019-11-21
AU2019269590A1 (en) 2020-12-03
US20210177982A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
JP7772597B2 (ja) 生物学的送達ビヒクルのための組成物及び方法
Mollé et al. Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery
Liu et al. Charge conversional biomimetic nanocomplexes as a multifunctional platform for boosting orthotopic glioblastoma RNAi therapy
Christie et al. Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection
Bi et al. Actively targeted nanoparticles for drug delivery to tumor
Ganesh et al. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors
Tam et al. Penetrating the blood–brain barrier by self-assembled 3D DNA nanocages as drug delivery vehicles for brain cancer therapy
US20190351071A1 (en) Structures and methods for gene therapy
Kotmakçı et al. Extracellular vesicles as natural nanosized delivery systems for small-molecule drugs and genetic material: steps towards the future nanomedicines
US20210177982A1 (en) Mucus-penetrating peptides, delivery vehicles and methods of therapy
US20230023615A1 (en) Compositions and methods for biological delivery vehicles
JP2012533587A (ja) 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート
WO2022260678A1 (en) Compositions and methods for biological delivery vehicles
US9976142B2 (en) Targeting molecule and a use thereof
Hall et al. Peptide/lipid-associated nucleic acids (PLANAs) as a multicomponent siRNA delivery system
EP4259099A1 (en) Biological delivery systems
JP7624951B2 (ja) リガンドイオノフォアコンジュゲート
Geng et al. Emerging landscape of cell-penetrating peptide-mediated organelle restoration and replacement
US11890352B2 (en) Plectin-targeted liposomes/PARP inhibitor in the treatment of cancer
CN116490215A (zh) 靶向介导的内吞药物递送
Mumcuoğlu Self-assembled peptide nanostructure delivery sytems for oligonucleotide therapy
Alshaer Functionalizing liposomes with aptamers for active targeting of tumor cells
ALSHAER L’UNIVERSITE PARIS-SACLAY
Xu Multimodal Therapeutic Strategy for Pancreatic Cancer: EGFR-Targeted Gelatin-Based Nanoparticles for Combination Wild-Type p53 Gene and Cytotoxic Drug Delivery
Alexander Peptide-mediated delivery of bioactive siRNAs for the treatment of oral cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210212